Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment
Open Access
- 16 April 2007
- journal article
- review article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (5) , 901-906
- https://doi.org/10.1111/j.1538-7836.2007.02410.x
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Angiogenesis Enhances Factor IX Delivery and Persistence from Retrievable Human Bioengineered Muscle ImplantsMolecular Therapy, 2006
- Stem cell–derived erythroid cells mediate long-term systemic protein deliveryNature Biotechnology, 2006
- Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodiesJournal of Clinical Investigation, 2006
- Cellular and genetic therapies for haemophiliaHaemophilia, 2006
- Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transferNature Medicine, 2006
- Correction of murine hemophilia a by hematopoietic stem cell gene therapyMolecular Therapy, 2005
- Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transferBlood, 2005
- Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapyProceedings of the National Academy of Sciences, 2005
- Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in miceBlood, 2004
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003